Recent developments in MOG-IgG associated neurological disorders
In the past few years, acquired demyelinating syndromes of the central nervous system associated with antibodies against myelin oligodendrocyte glycoprotein (MOG) have evolved into a new inflammatory disease entity distinct from neuromyelitis optica spectrum disorders or multiple sclerosis. The meti...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-07-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/1756286420945135 |
| _version_ | 1819278459841544192 |
|---|---|
| author | Harald Hegen Markus Reindl |
| author_facet | Harald Hegen Markus Reindl |
| author_sort | Harald Hegen |
| collection | DOAJ |
| description | In the past few years, acquired demyelinating syndromes of the central nervous system associated with antibodies against myelin oligodendrocyte glycoprotein (MOG) have evolved into a new inflammatory disease entity distinct from neuromyelitis optica spectrum disorders or multiple sclerosis. The meticulous clinical description of patients with MOG IgG antibodies (MOG-IgG) has been achieved by development and use of highly specific cell-based assays. MOG-IgG associated disorders comprise a wide spectrum of syndromes ranging from acute disseminated encephalomyelitis predominantly in children to optic neuritis or myelitis mostly in adults. In recent studies, phenotype of MOG-IgG associated disorders has further broadened with the description of cases of brainstem encephalitis, encephalitis with seizures and overlap syndromes with other types of autoimmune encephalitis. In this review, we provide an overview of current knowledge of MOG-IgG associated disorders, describe the clinical presentations identified, highlight differences from neuromyelitis optica spectrum disorders and multiple sclerosis, summarize clinical outcome and concepts of immune treatment, depict the underlying mechanisms of antibody pathogenicity and provide the methodological essentials of MOG-IgG assays. |
| first_indexed | 2024-12-24T00:12:21Z |
| format | Article |
| id | doaj.art-3b2ba4801f1b4a5c902abec450ecf37d |
| institution | Directory Open Access Journal |
| issn | 1756-2864 |
| language | English |
| last_indexed | 2024-12-24T00:12:21Z |
| publishDate | 2020-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Neurological Disorders |
| spelling | doaj.art-3b2ba4801f1b4a5c902abec450ecf37d2022-12-21T17:24:50ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28642020-07-011310.1177/1756286420945135Recent developments in MOG-IgG associated neurological disordersHarald HegenMarkus ReindlIn the past few years, acquired demyelinating syndromes of the central nervous system associated with antibodies against myelin oligodendrocyte glycoprotein (MOG) have evolved into a new inflammatory disease entity distinct from neuromyelitis optica spectrum disorders or multiple sclerosis. The meticulous clinical description of patients with MOG IgG antibodies (MOG-IgG) has been achieved by development and use of highly specific cell-based assays. MOG-IgG associated disorders comprise a wide spectrum of syndromes ranging from acute disseminated encephalomyelitis predominantly in children to optic neuritis or myelitis mostly in adults. In recent studies, phenotype of MOG-IgG associated disorders has further broadened with the description of cases of brainstem encephalitis, encephalitis with seizures and overlap syndromes with other types of autoimmune encephalitis. In this review, we provide an overview of current knowledge of MOG-IgG associated disorders, describe the clinical presentations identified, highlight differences from neuromyelitis optica spectrum disorders and multiple sclerosis, summarize clinical outcome and concepts of immune treatment, depict the underlying mechanisms of antibody pathogenicity and provide the methodological essentials of MOG-IgG assays.https://doi.org/10.1177/1756286420945135 |
| spellingShingle | Harald Hegen Markus Reindl Recent developments in MOG-IgG associated neurological disorders Therapeutic Advances in Neurological Disorders |
| title | Recent developments in MOG-IgG associated neurological disorders |
| title_full | Recent developments in MOG-IgG associated neurological disorders |
| title_fullStr | Recent developments in MOG-IgG associated neurological disorders |
| title_full_unstemmed | Recent developments in MOG-IgG associated neurological disorders |
| title_short | Recent developments in MOG-IgG associated neurological disorders |
| title_sort | recent developments in mog igg associated neurological disorders |
| url | https://doi.org/10.1177/1756286420945135 |
| work_keys_str_mv | AT haraldhegen recentdevelopmentsinmogiggassociatedneurologicaldisorders AT markusreindl recentdevelopmentsinmogiggassociatedneurologicaldisorders |